Results 161 to 170 of about 32,692 (251)

The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. [PDF]

Transl Oncol
Tsai TY, Kawabe M, Kaga AN, Okamoto K, Myers JN, Osman AA.   +5 more
europepmc   +1 more source

EphA2/SHP2/SOX8 Axis: A Novel Target for Regulation of Migration and Cetuximab Treatment Sensitivity in Oral Squamous Cell Carcinoma

Molecular Carcinogenesis, Volume 65, Issue 8, Page 977-988, August 2026.
ABSTRACT The development of resistance to anticancer therapies in cancer cell is a major challenge in the treatment of oral squamous cell carcinoma (OSCC), a common malignant tumor. Erythropoietin‐producing hepatocellular A2 (EphA2) affects several cancers, and this study examined its role in enhancing OSCC.
Dayong Yan, Lele Guo, Fei Pei, Ketao Zhong   +3 more
wiley   +1 more source

Comparative Analysis of Pathology Foundation Models for Automated Detection of Tertiary Lymphoid Structures in Hematoxylin-and-Eosin-Stained Digital Pathology Images. [PDF]

Comput Struct Biotechnol J
Guan M, Sun Y, Belete M, Muthuswamy A, Farma M, Kaufmann J, Lechpammer M, Sridhar S, Higgs BW, Si H.   +9 more
europepmc   +1 more source

Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

MedComm, Volume 7, Issue 8, August 2026.
Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge, Dong Han, Jing Wang, Xinyu Dai, Chen Ma, Feihong Chen   +5 more
wiley   +1 more source

Photon counting computed tomography in head and neck squamous cell carcinoma: iodine concentration and histopathological features. [PDF]

J Cancer Res Clin Oncol
Surov A, Diallo-Danebrock R, Sonnemann H, Roggel R, Scheer M, Volkenstein S, Wienke A, Borggrefe J.   +7 more
europepmc   +1 more source

MYC in Oncogenesis and Therapeutic Implications

MedComm, Volume 7, Issue 8, August 2026.
The MYC oncogene family (c‐MYC, N‐MYC, L‐MYC) functions as a central transcriptional hub orchestrating cancer progression through multiple interconnected pathways. This graphical abstract illustrates MYC's role as a multidimensional regulator positioned at the nexus of tumor microenvironment remodeling, metabolic reprogramming, and therapeutic ...
Na Zhang, Li Wei, Cuiping Tang, Peilong Lai, Wenbin Zhong, Hua You   +5 more
wiley   +1 more source

Integrated Single-Cell and Spatial Analysis Reveals Context-Dependent Myeloid-T Cell Interactions in Response to Immune Checkpoint Blockade in Head and Neck Cancer. [PDF]

Clin Cancer Res
Golfinos-Owens AE, Lozar T, Khatri P, Johns ED, Hu R, Harari PM, Lambert PF, Fitzpatrick MB, Dinh HQ.   +8 more
europepmc   +1 more source

METTL16 Promotes Head and Neck Squamous Cell Carcinoma Progression via m6A-Mediated Stabilization of SREBP2 mRNA and Enhanced Cholesterol Biosynthesis. [PDF]

Cancer Med
Ma X, Ding X, Deng J, Gao Q, Liu H, Yuan S, Xiao Z, Jiang R.   +7 more
europepmc   +1 more source

Epithelial YPEL3 Modulates CD8+ T‐Cell Infiltration and Tumor Progression Through CREB1–CXCL16 Signaling in HNSCC

Cancer Science, Volume 117, Issue 8, Page 2132-2151, August 2026.
YPEL3 functions as a tumor suppressor in HNSCC by inhibiting tumor progression and promoting apoptosis. Mechanistically, it enhances epithelial–immune crosstalk through the CREB1‐mediated CXCL16–CXCR6 axis, facilitating CD8+ T‐cell infiltration and highlighting its potential as a prognostic biomarker and immunotherapy target.
Yalun Li, Yumei Li, Caiyu Sun, Congxian Lu, Gang Chen, Tianshu Zhou, Bei Zhang, Xicheng Song   +7 more
wiley   +1 more source

TMEM92 drives EMT-associated invasiveness, cisplatin resistance, and immune suppression in head and neck squamous cell carcinoma. [PDF]

Sci Rep
He R, Wu Y, Wu C, Li L.
europepmc   +1 more source